Download Files:
Products Details
Product Description
– LJ-4517 is a potent A2AAR antagonist, with a Ki of 18.3 nM. LJ-4517 is potent in displacing the binding of [3H]ZM241385 (HY-19532) at WT A2AAR[1]. LJ-4517 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Web ID
– HY-151139
Shipping
– Room temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C19H21N5O3S
References
– [1]Shiriaeva A, et al. GPCR Agonist-to-Antagonist Conversion: Enabling the Design of Nucleoside Functional Switches for the A2A Adenosine Receptor. J Med Chem. 2022 Aug 17.
Molecular Weight
– 399.47
SMILES
– O[C@H]1[C@H](N2C(C3=CC=CS3)=NC4=C(N)N=C(C#CCCCC)N=C24)OC[C@H]1O
Clinical Information
– No Development Reported
Research Area
– Cancer; Inflammation/Immunology; Neurological Disease
Solubility
– 10 mM in DMSO
Target
– Adenosine Receptor
Isoform
– Adenosine A2A receptor (A2AR)
Pathway
– GPCR/G Protein
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
